StockMarketWire.com - Allergy Therapeutics said a study evaluating an allergy vaccine would now be split into two stages.

The study was originally planned for the 2020/2021 pollen season but would now take place over that season and the 2021/2022 season, too.

The stepwise approach had been designed with input from allergy experts.

It would enable a phase III-scale study to begin in the 2020/2021 season, followed by an interim review to gain insights into the trial, before continuing to the second part of the study.


At 3:01pm: [LON:AGY] Allergy Therapeutics PLC share price was 0p at 10.6p



Story provided by StockMarketWire.com